Short answer
Perspective Therapeutics, Inc. (CATX) filed an 8-K current report with the SEC on October 8, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). FDA Fast Track Designation granted to PSV359 for advanced FAP-positive solitary fibrous tumors.
Perspective Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA Fast Track Designation granted to PSV359 for advanced FAP-positive solitary fibrous tumors
- Adult patients with locally advanced unresectable and/or metastatic disease targeted
- Regulatory designation may enable more frequent FDA interaction and potential expedited development
- PSV359 remains investigational, with clinical and commercial outcomes still uncertain
Item EX-99.1 · Exhibit EX-99.1
- FDA Fast Track designation for PSV359 in FAP-positive solitary fibrous tumors, supporting expedited regulatory interaction
- Rare, serious cancer with limited treatment options, creating potential orphan-disease development opportunity
- PSV359 remains investigational in ongoing Phase 1/2a study NCT06710756, with safety, tolerability and dose selection still unresolved
- Fast Track may enable rolling review, Accelerated Approval or Priority Review, but each requires separate FDA criteria
- Broader FAP-targeted platform potential across multiple solid tumors, balanced against clinical, regulatory and funding risks
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Perspective Therapeutics, Inc. 8-K filings
Get the next CATX 8-K as it lands
Follow CATX for push alerts, or ask the research agent what this filing means.